Oligonucleotide (siRNA) · Gene silencing · developed by OPKO Health
Bevasiranib is an intravitreally administered agent studied in age-related macular degeneration, including the wet form.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00557791 | Phase 3 | Age Related Macular Degeneration | Withdrawn | OPK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Age Related Macular Degeneration
Updated Oct 25, 2026. Something wrong or missing? Report it on the OPK page.
See OPK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OPK catalysts and pipeline →